BT3 Company Report

Analyst Coverage

Research analysts covering BT3.

Recent press releases and 8-K filings for BT3.

Lineage Cell Therapeutics Provides Update on Cell Therapy Pipeline and Manufacturing Strategy

BT3

New Projects/Investments

Lineage Cell Therapeutics (BT3) is advancing its allogeneic cell therapy pipeline, with a focus on its OpRegen program for atrophic AMD, partnered with Roche and Genentech, which has demonstrated anatomical improvements and increased vision in clinical trials. Genentech is currently conducting a surgical optimization study for OpRegen, which is considered a multi-billion dollar opportunity.
The company has initiated a new clinical trial for its OPC1 program in spinal cord injury, treating both subacute and chronic patients, and has significantly improved its manufacturing process, delivery system, and formulation for this therapy.
Lineage emphasizes its core competency in manufacturing allogeneic, off-the-shelf cell therapies, highlighting its ability to control the process, ensure purity and potency, and achieve scalability for broad market supply.

Feb 11, 2025, 5:40 PM

Lineage Cell Therapeutics Presents at Oppenheimer Healthcare Conference

BT3

New Projects/Investments

Lineage Cell Therapeutics focuses on allogeneic cell therapies for "noncology" indications, primarily in neuro, utilizing a "replace and restore" approach.
Their lead program, OpRegen, partnered with Roche and Genentech, targets atrophic age-related macular degeneration (dry AMD) by transplanting RPE cells to improve vision and retinal structure. The partnership was extended with an additional service agreement in the first half of 2025.
The OPC1 program for spinal cord injury initiated an additional clinical trial on February 11, 2025, treating both subacute and, for the first time, chronic injury patients. The company has significantly improved OPC1 manufacturing processes, including a novel delivery system and a thaw-and-inject formulation.
Lineage emphasizes its manufacturing capabilities as a core competency, focusing on scalability and purity for off-the-shelf allogeneic therapies, which they believe is crucial for success in the cell therapy space.